European Society for Medical Oncology Asia Congress 2025 (ESMO Asia 2025)
Singapore 05 December 2025 - 07 December 2025
Zongertinib shows promise in Asians with advanced HER2-mutant NSCLC
Treatment with zongertinib in Asian patients with advanced HER2-mutant nonsmall cell lung cancer (NSCLC), who have received prior systemic therapy, delivers robust efficacy and elicits an acceptable safety profile, consistent with the overall global analysis, reports a China study.
Zongertinib shows promise in Asians with advanced HER2-mutant NSCLC
18 Jan 2026
Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients
The use of single tremelimumab (T) regular interval durvalumab (D), or STRIDE, results in a manageable safety profile in Asian patients with unresectable hepatocellular carcinoma (uHCC), as shown by the preliminary results of the SIERRA study.
Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients
17 Jan 2026
Tamoxifen interruption for pregnancy feasible in young breast cancer survivors
A real-world Asian study presented at ESMO Asia 2025 supports temporary tamoxifen interruption for young breast cancer survivors who are considering pregnancy.
Tamoxifen interruption for pregnancy feasible in young breast cancer survivors
08 Jan 2026
Ivonescimab trumps tislelizumab for squamous NSCLC in HARMONi-6
In the phase III HARMONi-6 trial, ivonescimab plus chemotherapy significantly improved progression-free survival (PFS) compared with tislelizumab plus chemo as first-line treatment for individuals with advanced squamous non-small cell lung cancer (NSCLC).